glp 1 name Market Overview: GLP-1 Agonists and the Obesity Market | Blog 5 GLP-1 trends to expect

Description

FDA approves Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

These medications work by mimicking the action of GLP-1, thereby helping to regulate blood sugar levels and reduce appetite

While effective, these treatments require monitoring due to potential side effects, especially in non-diabetic patients.This therapeutic advancement represents a revolution in the management of metabolic diseases and obesity.Despite their efficacy in managing obesity and metabolic disorders, GLP-1 and GIP receptor agonists can cause side effects, which are a common reason for therapy discontinuation